BioXcel Therapeutics Announces BXCL501 Met Primary Endpoint in Phase 1b Placebo-Controlled Trial in the Treatment of Agitation in Patients with Schizophrenia

July 22, 2019

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search